Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
Kentaro Tanaka, Hajime Asahina, Junji Kishimoto, Yoshihiro Miyata, Takahiro Uchida, Kana Watanabe, Kosuke Hamai, Taishi Harada, Yukari Tsubata, Shunichi Sugawara, Kunihiko Kobayashi, Kenji Sugio, Satoshi Oizumi, Isamu Okamoto
Topics & Concepts
OsimertinibMedicinePemetrexedT790MCarboplatinInternal medicineLung cancerOncologyTolerabilityClinical endpointAdverse effectChemotherapyClinical trialCancerErlotinibEpidermal growth factor receptorGefitinibCisplatinLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and Treatment